{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:22:57Z","timestamp":1790875377293,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) is a complicated maternally inherited disorder lacking of sensitive and specific biomarkers. The objective of this study was to investigate the serum neurofilament light chain (NfL) as a novel biomarker of neurological dysfunction in MELAS. Patients with different status of MELAS were enrolled in this study. The Mini-Mental State Examination (MMSE) was given to the participants to evaluate cognition status. Multiple functional MRI was performed on the participants. Blood samples were collected and the serum NfL concentrations were determined by the single-molecule array technology (Simoa). This study enrolled 23 patients with MELAS, 15 people in the acute attack phase of MELAS and 10 people in the remission phase, including 2 patients in both acute attack and remission phase. Sixteen healthy controls (HCs) were also enrolled. Serum NfL level increased significantly in patients with MELAS. Serum NfL level in the acute attack group (146.73 [120.91\u2013411.31] pg\/ml, median [IQR]) was higher than in the remission group (40.31 [19.54\u2013151.05] pg\/ml, median [IQR]) and HCs group (7.70 [6.13\u20139.78] pg\/ml, median [IQR]) (p\u2009&lt;\u20090.05). The level of NfL in the remission phase group was higher than in HCs group (p\u2009&lt;\u20090.05). A negative correlation was found between the serum NfL level and MMSE (p\u2009=\u20090.006, r\u2009=\u2009-0.650). The NfL concentration correlated positively with stroke-like lesion volume in the brain (r\u2009=\u20090.740, p\u2009&lt;\u20090.001). Serum NfL may serve as a novel biomarker for the neurological dysfunction in MELAS patients.<\/jats:p>","DOI":"10.1038\/s41598-021-81721-7","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T11:03:39Z","timestamp":1611227019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Neurofilament light is a novel biomarker for mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes"],"prefix":"10.1038","volume":"11","author":[{"given":"Yong-Sheng","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ne","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Shan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ying","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Hong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Bo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,21]]},"reference":[{"key":"81721_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/ana.410160409","volume":"16","author":"SG Pavlakis","year":"1984","unstructured":"Pavlakis, S. G., Phillips, P. C., DiMauro, S., De Vivo, D. C. & Rowland, L. P. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: A distinctive clinical syndrome. Ann. Neurol. 16, 481\u2013488. https:\/\/doi.org\/10.1002\/ana.410160409 (1984).","journal-title":"Ann. Neurol."},{"key":"81721_CR2","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1212\/01.wnl.0000436068.43384.ef","volume":"81","author":"RL Davis","year":"2013","unstructured":"Davis, R. L. et al. Fibroblast growth factor 21 is a sensitive biomarker of mitochondrial disease. Neurology 81, 1819\u20131826. https:\/\/doi.org\/10.1212\/01.wnl.0000436068.43384.ef (2013).","journal-title":"Neurology"},{"key":"81721_CR3","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/ana.24506","volume":"78","author":"S Yatsuga","year":"2015","unstructured":"Yatsuga, S. et al. Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders. Ann. Neurol. 78, 814\u2013823. https:\/\/doi.org\/10.1002\/ana.24506 (2015).","journal-title":"Ann. Neurol."},{"key":"81721_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejpn.2010.10.001","volume":"15","author":"M Magner","year":"2011","unstructured":"Magner, M. et al. Elevated CSF-lactate is a reliable marker of mitochondrial disorders in children even after brief seizures. Eur. J. Paediatr. Neurol. 15, 101\u2013108. https:\/\/doi.org\/10.1016\/j.ejpn.2010.10.001 (2011).","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"81721_CR5","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/jmri.25592","volume":"46","author":"Y Li","year":"2017","unstructured":"Li, Y., Lin, J., Sun, C., Zhao, C. & Li, H. Increased cerebral blood flow as a predictor of episodes in MELAS using multimodal MRI. J. Magn. Reson. Imaging 46, 915\u2013918. https:\/\/doi.org\/10.1002\/jmri.25592 (2017).","journal-title":"J. Magn. Reson. Imaging"},{"key":"81721_CR6","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1083\/jcb.122.6.1337","volume":"122","author":"MK Lee","year":"1993","unstructured":"Lee, M. K., Xu, Z., Wong, P. C. & Cleveland, D. W. Neurofilaments are obligate heteropolymers in vivo. J. Cell Biol. 122, 1337\u20131350 (1993).","journal-title":"J. Cell Biol."},{"key":"81721_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaneurol.2015.3037","volume":"73","author":"H Zetterberg","year":"2016","unstructured":"Zetterberg, H. et al. Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol. 73, 60\u201367. https:\/\/doi.org\/10.1001\/jamaneurol.2015.3037 (2016).","journal-title":"JAMA Neurol."},{"key":"81721_CR8","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1212\/wnl.0000000000004029","volume":"88","author":"K Poesen","year":"2017","unstructured":"Poesen, K. & De Schaepdryver, M. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology 88, 2302\u20132309. https:\/\/doi.org\/10.1212\/wnl.0000000000004029 (2017).","journal-title":"Neurology"},{"key":"81721_CR9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","volume":"81","author":"G Disanto","year":"2017","unstructured":"Disanto, G. et al. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann. Neurol. 81, 857\u2013870. https:\/\/doi.org\/10.1002\/ana.24954 (2017).","journal-title":"Ann. Neurol."},{"key":"81721_CR10","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1212\/wnl.0000000000004683","volume":"89","author":"L Novakova","year":"2017","unstructured":"Novakova, L. et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology 89, 2230\u20132237. https:\/\/doi.org\/10.1212\/wnl.0000000000004683 (2017).","journal-title":"Neurology"},{"key":"81721_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson, N., Andreasson, U., Zetterberg, H., Blennow, K. & Alzheimer\u2019s Disease Neuroimaging, I. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 74, 557\u2013566. https:\/\/doi.org\/10.1001\/jamaneurol.2016.6117 (2017).","journal-title":"JAMA Neurol."},{"key":"81721_CR12","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1212\/wnl.0000000000003680","volume":"88","author":"O Hansson","year":"2017","unstructured":"Hansson, O. et al. Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder. Neurology 88, 930\u2013937. https:\/\/doi.org\/10.1212\/wnl.0000000000003680 (2017).","journal-title":"Neurology"},{"key":"81721_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat7108","author":"LM Byrne","year":"2018","unstructured":"Byrne, L. M. et al. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington\u2019s disease. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aat7108 (2018).","journal-title":"Sci. Transl. Med."},{"key":"81721_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.mito.2018.07.002","volume":"46","author":"K Sofou","year":"2019","unstructured":"Sofou, K. et al. Cerebrospinal fluid neurofilament light is associated with survival in mitochondrial disease patients. Mitochondrion 46, 228\u2013235 (2019).","journal-title":"Mitochondrion"},{"key":"81721_CR15","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1212\/wnl.0000000000003154","volume":"87","author":"JD Rohrer","year":"2016","unstructured":"Rohrer, J. D. et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology 87, 1329\u20131336. https:\/\/doi.org\/10.1212\/wnl.0000000000003154 (2016).","journal-title":"Neurology"},{"key":"81721_CR16","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1212\/wnl.0000000000003912","volume":"88","author":"P Shahim","year":"2017","unstructured":"Shahim, P., Zetterberg, H., Tegner, Y. & Blennow, K. Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports. Neurology 88, 1788\u20131794. https:\/\/doi.org\/10.1212\/wnl.0000000000003912 (2017).","journal-title":"Neurology"},{"key":"81721_CR17","doi-asserted-by":"publisher","first-page":"e1104","DOI":"10.1212\/WNL.0000000000008088","volume":"93","author":"CH Lin","year":"2019","unstructured":"Lin, C. H. et al. Blood NfL: A biomarker for disease severity and progression in Parkinson disease. Neurology 93, e1104\u2013e1111. https:\/\/doi.org\/10.1212\/WNL.0000000000008088 (2019).","journal-title":"Neurology"},{"key":"81721_CR18","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","volume":"54","author":"J Kuhle","year":"2016","unstructured":"Kuhle, J. et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin. Chem. Lab. Med. 54, 1655\u20131661. https:\/\/doi.org\/10.1515\/cclm-2015-1195 (2016).","journal-title":"Clin. Chem. Lab. Med."},{"key":"81721_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.5853\/jos.2017.02565","volume":"20","author":"M Duering","year":"2018","unstructured":"Duering, M. et al. Serum neurofilament light chain levels are related to small vessel disease burden. J. Stroke 20, 228\u2013238. https:\/\/doi.org\/10.5853\/jos.2017.02565 (2018).","journal-title":"J. Stroke"},{"key":"81721_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ymgme.2015.06.004","volume":"116","author":"AW El-Hattab","year":"2015","unstructured":"El-Hattab, A. W. MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options. Mol. Genet. Metab. 116, 4\u201312. https:\/\/doi.org\/10.1016\/j.ymgme.2015.06.004 (2015).","journal-title":"Mol. Genet. Metab."},{"key":"81721_CR21","doi-asserted-by":"publisher","first-page":"e1338","DOI":"10.1212\/wnl.0000000000006282","volume":"91","author":"S Tiedt","year":"2018","unstructured":"Tiedt, S. et al. Serum neurofilament light: A biomarker of neuroaxonal injury after ischemic stroke. Neurology 91, e1338\u2013e1347. https:\/\/doi.org\/10.1212\/wnl.0000000000006282 (2018).","journal-title":"Neurology"},{"key":"81721_CR22","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1212\/WNL.0000000000004667","volume":"89","author":"PSJ Weston","year":"2017","unstructured":"Weston, P. S. J. et al. Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration. Neurology 89, 2167\u20132175. https:\/\/doi.org\/10.1212\/WNL.0000000000004667 (2017).","journal-title":"Neurology"},{"key":"81721_CR23","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1089\/neu.2016.4496","volume":"34","author":"J Ljungqvist","year":"2017","unstructured":"Ljungqvist, J., Zetterberg, H., Mitsis, M., Blennow, K. & Skoglund, T. Serum neurofilament light protein as a marker for diffuse axonal injury: Results from a case series study. J. Neurotrauma 34, 1124\u20131127. https:\/\/doi.org\/10.1089\/neu.2016.4496 (2017).","journal-title":"J. Neurotrauma"},{"key":"81721_CR24","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3389\/fnhum.2017.00567","volume":"11","author":"D Baldaranov","year":"2017","unstructured":"Baldaranov, D. et al. Longitudinal diffusion tensor imaging-based assessment of tract alterations: An application to amyotrophic lateral sclerosis. Front. Human Neurosci. 11, 567. https:\/\/doi.org\/10.3389\/fnhum.2017.00567 (2017).","journal-title":"Front. Human Neurosci."},{"key":"81721_CR25","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2214\/ajr.166.3.8623642","volume":"166","author":"IO Kim","year":"1996","unstructured":"Kim, I. O. et al. Mitochondrial myopathy-encephalopathy-lactic acidosis-and strokelike episodes (MELAS) syndrome: CT and MR findings in seven children. Am. J. Roentgenol. 166, 641\u2013645 (1996).","journal-title":"Am. J. Roentgenol."},{"key":"81721_CR26","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1097\/RCT.0000000000000712","volume":"42","author":"W Xu","year":"2018","unstructured":"Xu, W. et al. Conventional and diffusional magnetic resonance imaging features of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes in Chinese patients: A study of 40 cases. J. Comput. Assist. Tomogr. 42, 510\u2013516. https:\/\/doi.org\/10.1097\/RCT.0000000000000712 (2018).","journal-title":"J. Comput. Assist. Tomogr."},{"key":"81721_CR27","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/s1474-4422(17)30124-2","volume":"16","author":"LM Byrne","year":"2017","unstructured":"Byrne, L. M. et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington\u2019s disease: A retrospective cohort analysis. Lancet. Neurol. 16, 601\u2013609. https:\/\/doi.org\/10.1016\/s1474-4422(17)30124-2 (2017).","journal-title":"Lancet. Neurol."},{"key":"81721_CR28","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/j.bbagen.2011.03.015","volume":"619\u2013624","author":"S Yatsuga","year":"1820","unstructured":"Yatsuga, S. et al. MELAS: A nationwide prospective cohort study of 96 patients in Japan. Biochim. Biophys. Acta 619\u2013624, 2012. https:\/\/doi.org\/10.1016\/j.bbagen.2011.03.015 (1820).","journal-title":"Biochim. Biophys. Acta"},{"key":"81721_CR29","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.mito.2013.09.007","volume":"13","author":"M Ikawa","year":"2013","unstructured":"Ikawa, M. et al. Detection of preclinically latent hyperperfusion due to stroke-like episodes by arterial spin-labeling perfusion MRI in MELAS patients. Mitochondrion 13, 676\u2013680. https:\/\/doi.org\/10.1016\/j.mito.2013.09.007 (2013).","journal-title":"Mitochondrion"}],"updated-by":[{"DOI":"10.1038\/s41598-021-94591-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81721-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81721-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81721-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T02:17:46Z","timestamp":1670033866000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81721-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,21]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["81721"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-81721-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,21]]},"assertion":[{"value":"11 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-021-94591-w","URL":"https:\/\/doi.org\/10.1038\/s41598-021-94591-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2001"}}